Stocks Health care ALZN

NASDAQ · Health care

Alzamend Neuro, Inc. (ALZN)

It posted a net loss of $9.1M. At July 31, 2026 it held $7.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 10, 2026.

Watch ALZN in 60 seconds

Follow ALZN

Free, no password. An email when ALZN files with the SEC.

Key facts about Alzamend Neuro, Inc.

Net worth

Alzamend Neuro, Inc. has a market value (market cap) of $6.3M at the latest share price, and shareholders' equity of $5.8M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2026 operations used $8.1M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 10, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR

Next earnings report

Alzamend Neuro, Inc.'s next report is expected around December 8, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Alzamend Neuro, Inc. does

Alzamend Neuro, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALZN.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Alzamend Neuro, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 29, 2026
   Investor disclosure 8-K
2. September 10, 2026
   Quarterly report 10-Q · period to July 31, 2026Diluted EPS -$0.68 versus -$1.28.
3. August 28, 2026
   Preliminary proxy statement PRE 14A
4. August 21, 2026
   IPO registration S-1
5. August 3, 2026
   Material agreement 8-K
6. July 22, 2026
   Annual report 10-K · period to April 30, 2026Diluted EPS -$2.63 versus -$11.32.
7. July 21, 2026
   Other event 8-K
8. April 17, 2026
   Shareholder vote results 8-K
9. March 20, 2026
   Stock exchange listing notice 8-K
10. March 11, 2026
    Quarterly report 10-Q · period to January 31, 2026Diluted EPS -$0.58 versus -$1.75.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 31, 2026. Insider transactions on SEC

Insider trades

What the people running Alzamend Neuro, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $3.1K worth of shares in the last 90 days and bought none on the open market.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ALZN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Milton C. Ault, III 4.4% (October 7, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 116,648 shares in total, about $152.8K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ALZN

What does Alzamend Neuro, Inc. do?

Alzamend Neuro, Inc. is a company in the Health care sector, listed on NASDAQ as ALZN. Its shares trade on NASDAQ under the ticker ALZN.

What is Alzamend Neuro, Inc.'s net worth?

Alzamend Neuro, Inc. has a market value (market cap) of $6.3M at the latest share price, and shareholders' equity of $5.8M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Alzamend Neuro, Inc. profitable?

No. Over the twelve months to July 31, 2026 it reported a net loss of $9.1M.

When did Alzamend Neuro, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on September 10, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the investor disclosure from September 29, 2026.

When is Alzamend Neuro, Inc.'s next earnings report?

Alzamend Neuro, Inc.'s next report is expected around December 8, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare ALZN with

Compare ALZN with any company

Follow ALZN

Get an email when Alzamend Neuro, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ALZN

Free, no password. An email when ALZN files with the SEC.

Where the numbers come from

Financial figures are the values Alzamend Neuro, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.